

## NEXT GENERATION BIOSCIENCE LEADERS



**Carol A. Nancy, Ph.D.**

**Founder and Chief Executive Officer  
Sequella, Inc.**

**Dr. Carol A. Nancy** is currently founder and Chief Executive Officer of Sequella, Inc., a twelve year-old privately-held pharmaceutical company that commercializes new and more effective treatments for serious life-threatening infectious diseases, including tuberculosis (TB). Sequella has a new TB drug that will begin Phase 2 efficacy studies in Africa in 2H 2010, and an extensive pipeline of earlier-stage drugs moving to the clinic in various infectious disease indications. Sequella has ongoing research collaborations with large pharmaceutical companies and academic centers for development of new drugs for neglected diseases. Sequella raised nearly \$64M to date from institutional and individual investors, and peer-reviewed grants.

Prior to Sequella, Dr. Nancy was Executive Vice President and Chief Scientific Officer at EntreMed, Inc., from 1993 through its successful public offering in June 1996. She left EntreMed in November 1996 to establish Sequella, Inc. and was part-time Chief Scientific Officer (1997-1998) for Anergen, Inc., a California company focused on autoimmune diseases. There, she reorganized the scientific staff and approach, and positioned the company for acquisition by Corixa Corporation in December 1998.

Dr. Nancy became full time CEO and Chair of the Board of Sequella in January 1999. She is a member of the Board of Directors of for-profit companies (Social and Scientific Systems) and non-profit agencies (Sequella Foundation, Women in Bio, Sloan Biotechnology Industry Organization, Walters Art Museum, among others) and on a number of committees in global health organizations. Prior to her business experience, Dr. Nancy was career scientist and science manager for 17 years at the Walter Reed Army Institute of Research in Washington, DC, where she studied tropical

infectious diseases. She has published over 150 scientific papers to date.

Dr. Nancy was elected to the American Academy of Microbiology in 1985. She maintains strong ties to the scientific research community, was President of the American Society for Microbiology (1996) and the Society for Leukocyte Biology (1993), and was on the Board of the National Academy of Science, National Research Council (1996-2001). She is an adjunct faculty member of both the Department of Biology at the Catholic University of America, and the Department of Tropical Diseases at the George Washington University, Washington, DC. She earned her A.B., M.S., and Ph.D. degrees from the Catholic University of America in Washington, DC, and in 2002 she was awarded the Lifetime Achievement Award in Science from this institution.

Dr. Nancy was singled out as a Top 50 Innovator in the U.S. by Inc. Magazine in 2002, named Entrepreneur of the Year by Women in BIO in 2004, the state of Maryland named her in its Top 100 Business Women in 2005, and the Washington Business Journal named her as a top 25 female executive in the Washington DC metropolitan area in 2005. In 2006, she received a National Leadership Award in Healthcare from the National Urban Technology Center in New York City, and in 2007 she was honored with a Special Outstanding Achievement Award for Clinical Trials by Women in BIO. In December 2009 she was awarded the Humanitarian Award, *Hope is a Vaccine*, by the Global Alliance for Immunization against Aids (GAIA) for her work to create new drugs for TB.

Dr. Nancy is married to Monte S. Meltzer, M.D., has 5 children and 3 grandchildren, and lives in Washington, DC.